Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 227

1.

Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants.

Eide CA, Zabriskie MS, Savage Stevens SL, Antelope O, Vellore NA, Than H, Schultz AR, Clair P, Bowler AD, Pomicter AD, Yan D, Senina AV, Qiang W, Kelley TW, Szankasi P, Heinrich MC, Tyner JW, Rea D, Cayuela JM, Kim DW, Tognon CE, O'Hare T, Druker BJ, Deininger MW.

Cancer Cell. 2019 Oct 14;36(4):431-443.e5. doi: 10.1016/j.ccell.2019.08.004. Epub 2019 Sep 19.

PMID:
31543464
2.

KIT-Dependent and KIT-Independent Genomic Heterogeneity of Resistance in Gastrointestinal Stromal Tumors - TORC1/2 Inhibition as Salvage Strategy.

Mühlenberg T, Ketzer J, Heinrich MC, Grunewald S, Marino-Enriquez A, Trautmann M, Hartmann W, Wardelmann E, Treckmann J, Worm K, Bertram S, Herold T, Schildhaus HU, Glimm H, Stenzinger A, Brors B, Horak P, Hohenberger P, Fröhling S, Fletcher JA, Bauer S.

Mol Cancer Ther. 2019 Jul 15. doi: 10.1158/1535-7163.MCT-18-1224. [Epub ahead of print]

PMID:
31308077
3.

Correction: Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours.

Serrano C, Mariño-Enríquez A, Tao DL, Ketzer J, Eilers G, Zhu M, Yu C, Mannan AM, Rubin BP, Demetri GD, Raut CP, Presnell A, McKinley A, Heinrich MC, Czaplinski JT, Sicinska E, Bauer S, George S, Fletcher JA.

Br J Cancer. 2019 Jul;121(3):281. doi: 10.1038/s41416-019-0487-5.

4.

Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants.

Smith BD, Kaufman MD, Lu WP, Gupta A, Leary CB, Wise SC, Rutkoski TJ, Ahn YM, Al-Ani G, Bulfer SL, Caldwell TM, Chun L, Ensinger CL, Hood MM, McKinley A, Patt WC, Ruiz-Soto R, Su Y, Telikepalli H, Town A, Turner BA, Vogeti L, Vogeti S, Yates K, Janku F, Abdul Razak AR, Rosen O, Heinrich MC, Flynn DL.

Cancer Cell. 2019 May 13;35(5):738-751.e9. doi: 10.1016/j.ccell.2019.04.006.

PMID:
31085175
5.

Correction to: Survival in advanced GIST has improved over time and correlates with increased access to post-imatinib tyrosine kinase inhibitors: results from Life Raft Group Registry.

Call JW, Wang Y, Montoya D, Scherzer NJ, Heinrich MC.

Clin Sarcoma Res. 2019 May 7;9:7. doi: 10.1186/s13569-019-0117-2. eCollection 2019.

6.

Survival in advanced GIST has improved over time and correlates with increased access to post-imatinib tyrosine kinase inhibitors: results from Life Raft Group Registry.

Call JW, Wang Y, Montoya D, Scherzer NJ, Heinrich MC.

Clin Sarcoma Res. 2019 Apr 2;9:4. doi: 10.1186/s13569-019-0114-5. eCollection 2019. Erratum in: Clin Sarcoma Res. 2019 May 7;9:7.

7.

Biomarker results from a phase II study of MEK1/2 inhibitor binimetinib (MEK162) in patients with advanced NRAS- or BRAF-mutated melanoma.

van Herpen CML, Agarwala SS, Hauschild A, Berking C, Beck JT, Schadendorf D, Jansen R, Queirolo P, Ascierto PA, Blank CU, Heinrich MC, Pal RR, Derti A, Antona V, Nauwelaerts H, Zubel A, Dummer R.

Oncotarget. 2019 Mar 5;10(19):1850-1859. doi: 10.18632/oncotarget.26753. eCollection 2019 Mar 5.

8.

Rates of deep molecular response by digital and conventional PCR with frontline nilotinib in newly diagnosed chronic myeloid leukemia: a landmark analysis.

Berdeja JG, Heinrich MC, Dakhil SR, Goldberg SL, Wadleigh M, Kuriakose P, Cortes J, Radich J, Helton B, Rizzieri D, Paley C, Dautaj I, Mauro MJ.

Leuk Lymphoma. 2019 Oct;60(10):2384-2393. doi: 10.1080/10428194.2019.1590569. Epub 2019 Mar 26.

PMID:
30912699
9.

Genomic aberrations in cell cycle genes predict progression of KIT-mutant gastrointestinal stromal tumors (GISTs).

Heinrich MC, Patterson J, Beadling C, Wang Y, Debiec-Rychter M, Dewaele B, Corless CL, Duensing A, Raut CP, Rubin B, Ordog T, van de Rijn M, Call J, Mühlenberg T, Fletcher JA, Bauer S.

Clin Sarcoma Res. 2019 Mar 5;9:3. doi: 10.1186/s13569-019-0112-7. eCollection 2019.

10.

Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours.

Serrano C, Mariño-Enríquez A, Tao DL, Ketzer J, Eilers G, Zhu M, Yu C, Mannan AM, Rubin BP, Demetri GD, Raut CP, Presnell A, McKinley A, Heinrich MC, Czaplinski JT, Sicinska E, Bauer S, George S, Fletcher JA.

Br J Cancer. 2019 Mar;120(6):612-620. doi: 10.1038/s41416-019-0389-6. Epub 2019 Feb 22. Erratum in: Br J Cancer. 2019 May 23;:.

PMID:
30792533
11.

High expression of class III β-tubulin in upper gastrointestinal cancer types.

Höflmayer D, Öztürk E, Schroeder C, Hube-Magg C, Blessin NC, Simon R, Lang DS, Neubauer E, Göbel C, Heinrich MC, Fraune C, Möller K, Armbrust M, Freytag M, Hinsch A, Lühr C, Noack M, Reiswich V, Weidemann S, Bockhorn M, Perez D, Izbicki JR, Sauter G, Jacobsen F.

Oncol Lett. 2018 Dec;16(6):7139-7145. doi: 10.3892/ol.2018.9502. Epub 2018 Sep 25.

12.

LMTK3 is essential for oncogenic KIT expression in KIT-mutant GIST and melanoma.

Klug LR, Bannon AE, Javidi-Sharifi N, Town A, Fleming WH, VanSlyke JK, Musil LS, Fletcher JA, Tyner JW, Heinrich MC.

Oncogene. 2019 Feb;38(8):1200-1210. doi: 10.1038/s41388-018-0508-5. Epub 2018 Sep 21.

13.

Translational insights into gastrointestinal stromal tumor and current clinical advances.

Hemming ML, Heinrich MC, Bauer S, George S.

Ann Oncol. 2018 Oct 1;29(10):2037-2045. doi: 10.1093/annonc/mdy309.

PMID:
30101284
14.

Structural and clinical consequences of activation loop mutations in class III receptor tyrosine kinases.

Klug LR, Kent JD, Heinrich MC.

Pharmacol Ther. 2018 Nov;191:123-134. doi: 10.1016/j.pharmthera.2018.06.016. Epub 2018 Jun 30. Review.

PMID:
29964125
15.

PSCA expression is associated with favorable tumor features and reduced PSA recurrence in operated prostate cancer.

Heinrich MC, Göbel C, Kluth M, Bernreuther C, Sauer C, Schroeder C, Möller-Koop C, Hube-Magg C, Lebok P, Burandt E, Sauter G, Simon R, Huland H, Graefen M, Heinzer H, Schlomm T, Heumann A.

BMC Cancer. 2018 May 31;18(1):612. doi: 10.1186/s12885-018-4547-7.

16.

Integrated Molecular Characterization of Gastrointestinal Stromal Tumors (GIST) Harboring the Rare D842V Mutation in PDGFRA Gene.

Indio V, Astolfi A, Tarantino G, Urbini M, Patterson J, Nannini M, Saponara M, Gatto L, Santini D, do Valle IF, Castellani G, Remondini D, Fiorentino M, von Mehren M, Brandi G, Biasco G, Heinrich MC, Pantaleo MA.

Int J Mol Sci. 2018 Mar 4;19(3). pii: E732. doi: 10.3390/ijms19030732.

17.

A precision therapy against cancers driven by KIT/PDGFRA mutations.

Evans EK, Gardino AK, Kim JL, Hodous BL, Shutes A, Davis A, Zhu XJ, Schmidt-Kittler O, Wilson D, Wilson K, DiPietro L, Zhang Y, Brooijmans N, LaBranche TP, Wozniak A, Gebreyohannes YK, Schöffski P, Heinrich MC, DeAngelo DJ, Miller S, Wolf B, Kohl N, Guzi T, Lydon N, Boral A, Lengauer C.

Sci Transl Med. 2017 Nov 1;9(414). pii: eaao1690. doi: 10.1126/scitranslmed.aao1690.

PMID:
29093181
18.

Biochemical, Molecular, and Clinical Characterization of Succinate Dehydrogenase Subunit A Variants of Unknown Significance.

Bannon AE, Kent J, Forquer I, Town A, Klug LR, McCann K, Beadling C, Harismendy O, Sicklick JK, Corless C, Shinde U, Heinrich MC.

Clin Cancer Res. 2017 Nov 1;23(21):6733-6743. doi: 10.1158/1078-0432.CCR-17-1397. Epub 2017 Jul 19.

19.

Gastrointestinal stromal tumours of the oesophagus: a clinicopathological and molecular analysis of 27 cases.

Kang G, Kang Y, Kim KH, Ha SY, Kim JY, Shim YM, Heinrich MC, Kim KM, Corless CL.

Histopathology. 2017 Nov;71(5):805-812. doi: 10.1111/his.13292. Epub 2017 Sep 6.

PMID:
28644569
20.

Defining the Impact of Adjuvant Therapy in Molecularly Defined Subsets of Gastrointestinal Stromal Tumor : From Lumping to Splitting.

Heinrich MC, Corless CL, Demetri GD.

JAMA Oncol. 2017 May 1;3(5):597-599. doi: 10.1001/jamaoncol.2016.5740. No abstract available.

PMID:
28334361
21.

Using molecular diagnostic testing to personalize the treatment of patients with gastrointestinal stromal tumors.

Bannon AE, Klug LR, Corless CL, Heinrich MC.

Expert Rev Mol Diagn. 2017 May;17(5):445-457. doi: 10.1080/14737159.2017.1308826. Epub 2017 Mar 27. Review.

PMID:
28317407
22.

MAX inactivation is an early event in GIST development that regulates p16 and cell proliferation.

Schaefer IM, Wang Y, Liang CW, Bahri N, Quattrone A, Doyle L, Mariño-Enríquez A, Lauria A, Zhu M, Debiec-Rychter M, Grunewald S, Hechtman JF, Dufresne A, Antonescu CR, Beadling C, Sicinska ET, van de Rijn M, Demetri GD, Ladanyi M, Corless CL, Heinrich MC, Raut CP, Bauer S, Fletcher JA.

Nat Commun. 2017 Mar 8;8:14674. doi: 10.1038/ncomms14674.

23.

Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033.

Heinrich MC, Rankin C, Blanke CD, Demetri GD, Borden EC, Ryan CW, von Mehren M, Blackstein ME, Priebat DA, Tap WD, Maki RG, Corless CL, Fletcher JA, Owzar K, Crowley JJ, Benjamin RS, Baker LH.

JAMA Oncol. 2017 Jul 1;3(7):944-952. doi: 10.1001/jamaoncol.2016.6728. Erratum in: JAMA Oncol. 2017 Jul 1;3(7):1002.

24.

PDGFRA Antibody for Soft Tissue Sarcoma.

Klug LR, Heinrich MC.

Cell. 2017 Feb 9;168(4):555. doi: 10.1016/j.cell.2017.01.028.

25.

FGFR1 and NTRK3 actionable alterations in "Wild-Type" gastrointestinal stromal tumors.

Shi E, Chmielecki J, Tang CM, Wang K, Heinrich MC, Kang G, Corless CL, Hong D, Fero KE, Murphy JD, Fanta PT, Ali SM, De Siena M, Burgoyne AM, Movva S, Madlensky L, Heestand GM, Trent JC, Kurzrock R, Morosini D, Ross JS, Harismendy O, Sicklick JK.

J Transl Med. 2016 Dec 14;14(1):339.

26.

Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy.

Ben-Ami E, Barysauskas CM, von Mehren M, Heinrich MC, Corless CL, Butrynski JE, Morgan JA, Wagner AJ, Choy E, Yap JT, Van den Abbeele AD, Solomon SM, Fletcher JA, Demetri GD, George S.

Ann Oncol. 2016 Sep;27(9):1794-9. doi: 10.1093/annonc/mdw228. Epub 2016 Jul 1.

27.

Dose-escalation study of a second-generation non-ansamycin HSP90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic gastrointestinal stromal tumour.

Wagner AJ, Agulnik M, Heinrich MC, Mahadevan D, Riedel RF, von Mehren M, Trent J, Demetri GD, Corless CL, Yule M, Lyons JF, Oganesian A, Keer H.

Eur J Cancer. 2016 Jul;61:94-101. doi: 10.1016/j.ejca.2016.03.076. Epub 2016 May 5.

28.

Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial.

Reichardt P, Demetri GD, Gelderblom H, Rutkowski P, Im SA, Gupta S, Kang YK, Schöffski P, Schuette J, Soulières D, Blay JY, Goldstein D, Fly K, Huang X, Corsaro M, Lechuga MJ, Martini JF, Heinrich MC.

BMC Cancer. 2016 Jan 15;16:22. doi: 10.1186/s12885-016-2051-5.

29.

SDHC methylation in gastrointestinal stromal tumors (GIST): a case report.

Urbini M, Astolfi A, Indio V, Heinrich MC, Corless CL, Nannini M, Ravegnini G, Biasco G, Pantaleo MA.

BMC Med Genet. 2015 Sep 28;16:87. doi: 10.1186/s12881-015-0233-7.

30.

Genotyping and immunohistochemistry of gastrointestinal stromal tumors: An update.

Rubin BP, Heinrich MC.

Semin Diagn Pathol. 2015 Sep;32(5):392-9. doi: 10.1053/j.semdp.2015.02.017. Epub 2015 Feb 7. Review.

PMID:
25766843
31.

Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition.

Carvajal RD, Lawrence DP, Weber JS, Gajewski TF, Gonzalez R, Lutzky J, O'Day SJ, Hamid O, Wolchok JD, Chapman PB, Sullivan RJ, Teitcher JB, Ramaiya N, Giobbie-Hurder A, Antonescu CR, Heinrich MC, Bastian BC, Corless CL, Fletcher JA, Hodi FS.

Clin Cancer Res. 2015 May 15;21(10):2289-96. doi: 10.1158/1078-0432.CCR-14-1630. Epub 2015 Feb 18.

32.

Crosstalk between KIT and FGFR3 Promotes Gastrointestinal Stromal Tumor Cell Growth and Drug Resistance.

Javidi-Sharifi N, Traer E, Martinez J, Gupta A, Taguchi T, Dunlap J, Heinrich MC, Corless CL, Rubin BP, Druker BJ, Tyner JW.

Cancer Res. 2015 Mar 1;75(5):880-91. doi: 10.1158/0008-5472.CAN-14-0573. Epub 2014 Nov 28.

33.

Combination therapy for KIT-mutant mast cells: targeting constitutive NFAT and KIT activity.

Macleod AC, Klug LR, Patterson J, Griffith DJ, Beadling C, Town A, Heinrich MC.

Mol Cancer Ther. 2014 Dec;13(12):2840-51. doi: 10.1158/1535-7163.MCT-13-0830. Epub 2014 Sep 24.

34.

Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.

Garner AP, Gozgit JM, Anjum R, Vodala S, Schrock A, Zhou T, Serrano C, Eilers G, Zhu M, Ketzer J, Wardwell S, Ning Y, Song Y, Kohlmann A, Wang F, Clackson T, Heinrich MC, Fletcher JA, Bauer S, Rivera VM.

Clin Cancer Res. 2014 Nov 15;20(22):5745-5755. doi: 10.1158/1078-0432.CCR-14-1397. Epub 2014 Sep 19.

35.

Integrated genomic study of quadruple-WT GIST (KIT/PDGFRA/SDH/RAS pathway wild-type GIST).

Nannini M, Astolfi A, Urbini M, Indio V, Santini D, Heinrich MC, Corless CL, Ceccarelli C, Saponara M, Mandrioli A, Lolli C, Ercolani G, Brandi G, Biasco G, Pantaleo MA.

BMC Cancer. 2014 Sep 20;14:685. doi: 10.1186/1471-2407-14-685.

36.

Quadruple wild-type (WT) GIST: defining the subset of GIST that lacks abnormalities of KIT, PDGFRA, SDH, or RAS signaling pathways.

Pantaleo MA, Nannini M, Corless CL, Heinrich MC.

Cancer Med. 2015 Jan;4(1):101-3. doi: 10.1002/cam4.325. Epub 2014 Aug 28.

37.

KRAS and KIT Gatekeeper Mutations Confer Polyclonal Primary Imatinib Resistance in GI Stromal Tumors: Relevance of Concomitant Phosphatidylinositol 3-Kinase/AKT Dysregulation.

Serrano C, Wang Y, Mariño-Enríquez A, Lee JC, Ravegnini G, Morgan JA, Bertagnolli MM, Beadling C, Demetri GD, Corless CL, Heinrich MC, Fletcher JA.

J Clin Oncol. 2015 Aug 1;33(22):e93-6. doi: 10.1200/JCO.2013.48.7488. Epub 2014 Mar 31. No abstract available.

38.

Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial.

Corless CL, Ballman KV, Antonescu CR, Kolesnikova V, Maki RG, Pisters PW, Blackstein ME, Blanke CD, Demetri GD, Heinrich MC, von Mehren M, Patel S, McCarter MD, Owzar K, DeMatteo RP.

J Clin Oncol. 2014 May 20;32(15):1563-70. doi: 10.1200/JCO.2013.51.2046. Epub 2014 Mar 17. Erratum in: J Clin Oncol. 2014 Oct 20;32(30):3462.

39.

Regorafenib for treatment of advanced gastrointestinal stromal tumors.

Overton LC, Heinrich MC.

Expert Opin Pharmacother. 2014 Mar;15(4):549-58. doi: 10.1517/14656566.2014.877888. Epub 2014 Jan 10. Review.

PMID:
24405315
40.

Genetic profiling to determine risk of relapse-free survival in high-risk localized prostate cancer.

Barnett CM, Heinrich MC, Lim J, Nelson D, Beadling C, Warrick A, Neff T, Higano CS, Garzotto M, Qian D, Corless CL, Thomas GV, Beer TM.

Clin Cancer Res. 2014 Mar 1;20(5):1306-12. doi: 10.1158/1078-0432.CCR-13-1775. Epub 2013 Dec 18.

41.

Gene expression of the IGF pathway family distinguishes subsets of gastrointestinal stromal tumors wild type for KIT and PDGFRA.

Beadling C, Patterson J, Justusson E, Nelson D, Pantaleo MA, Hornick JL, Chacón M, Corless CL, Heinrich MC.

Cancer Med. 2013 Feb;2(1):21-31. doi: 10.1002/cam4.57. Epub 2013 Feb 3.

42.

Gastrointestinal stromal tumors: molecular markers and genetic subtypes.

Barnett CM, Corless CL, Heinrich MC.

Hematol Oncol Clin North Am. 2013 Oct;27(5):871-88. doi: 10.1016/j.hoc.2013.07.003. Epub 2013 Aug 26. Review.

PMID:
24093165
43.

Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.

Hodi FS, Corless CL, Giobbie-Hurder A, Fletcher JA, Zhu M, Marino-Enriquez A, Friedlander P, Gonzalez R, Weber JS, Gajewski TF, O'Day SJ, Kim KB, Lawrence D, Flaherty KT, Luke JJ, Collichio FA, Ernstoff MS, Heinrich MC, Beadling C, Zukotynski KA, Yap JT, Van den Abbeele AD, Demetri GD, Fisher DE.

J Clin Oncol. 2013 Sep 10;31(26):3182-90. doi: 10.1200/JCO.2012.47.7836. Epub 2013 Jun 17.

44.

Cell cycle-dependent activity of the novel dual PI3K-MTORC1/2 inhibitor NVP-BGT226 in acute leukemia.

Kampa-Schittenhelm KM, Heinrich MC, Akmut F, Rasp KH, Illing B, Döhner H, Döhner K, Schittenhelm MM.

Mol Cancer. 2013 May 24;12:46. doi: 10.1186/1476-4598-12-46.

45.

Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms.

Kampa-Schittenhelm KM, Heinrich MC, Akmut F, Döhner H, Döhner K, Schittenhelm MM.

Mol Cancer. 2013 Mar 7;12:19. doi: 10.1186/1476-4598-12-19.

46.

BRAF mutant gastrointestinal stromal tumor: first report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance.

Falchook GS, Trent JC, Heinrich MC, Beadling C, Patterson J, Bastida CC, Blackman SC, Kurzrock R.

Oncotarget. 2013 Feb;4(2):310-5.

47.

Whole-exome sequencing identifies a recurrent NAB2-STAT6 fusion in solitary fibrous tumors.

Chmielecki J, Crago AM, Rosenberg M, O'Connor R, Walker SR, Ambrogio L, Auclair D, McKenna A, Heinrich MC, Frank DA, Meyerson M.

Nat Genet. 2013 Feb;45(2):131-2. doi: 10.1038/ng.2522. Epub 2013 Jan 13.

48.

Combining highly multiplexed PCR with semiconductor-based sequencing for rapid cancer genotyping.

Beadling C, Neff TL, Heinrich MC, Rhodes K, Thornton M, Leamon J, Andersen M, Corless CL.

J Mol Diagn. 2013 Mar;15(2):171-6. doi: 10.1016/j.jmoldx.2012.09.003. Epub 2012 Dec 27.

PMID:
23274167
49.

Loss of succinate dehydrogenase subunit B (SDHB) expression is limited to a distinctive subset of gastric wild-type gastrointestinal stromal tumours: a comprehensive genotype-phenotype correlation study.

Doyle LA, Nelson D, Heinrich MC, Corless CL, Hornick JL.

Histopathology. 2012 Nov;61(5):801-9. doi: 10.1111/j.1365-2559.2012.04300.x. Epub 2012 Jul 17.

PMID:
22804613
50.

Regorafenib induces rapid and reversible changes in plasma nitric oxide and endothelin-1.

de Jesus-Gonzalez N, Robinson E, Penchev R, von Mehren M, Heinrich MC, Tap W, Wang Q, Demetri G, George S, Humphreys BD.

Am J Hypertens. 2012 Oct;25(10):1118-23. doi: 10.1038/ajh.2012.97. Epub 2012 Jul 12.

Supplemental Content

Loading ...
Support Center